Specifically, as pointed out, the supplementary estimates (A) provide re-profiling, both for aspects of therapeutics and making sure we are well prepared. As Dr. Tam pointed out earlier, COVID is not over yet, so we continue to build from where we started.
As we move forward, and as was mentioned, the medical countermeasures will still be very effective tools we would likely want to have in our arsenal in order to make sure we are prepared. In fact, a lot more emphasis will be on preparedness as we go further, whether it's on capacity-building or using new tools. In that context, when we talk about...whether it's domestic biomanufacturing or health human resources, those are all important components in terms of us being ready and the investment being there.
In reality, the lessons learned from this pandemic allow us to make those strategic investments, whether they're in capacity, expertise or tools, including medical countermeasures and therapeutics we can utilize as we move forward in our quest to get past this pandemic.